Option Care Health (OPCH) Q2 2026 Earnings Call Transcript

Option Care Health reported Q2 net revenue of $1.44B (+1.9% YoY; +7% sequential) alongside adjusted EBITDA of $117.5M (+3% YoY; +12% sequential) and adjusted EPS of $0.45 (+9.8% YoY). The company maintained 2026 revenue guidance at $5.675B–$5.775B but narrowed adjusted EBITDA to $480M–$495M and adjusted EPS to $1.85–$1.92, while targeting at least $320M operating cash flow. Management also repurchased $150M of stock (~5% of shares outstanding), leaving $525M remaining under authorization, and cited ongoing CID stabilization and AI-enabled operational improvements as key drivers.

Analysis

The key read-through is that OPCH is finally turning the business from a low-growth, reimbursement-driven story into a self-help and mix story. The commercial reset, clinic expansion, and workflow automation are all early indicators of operating leverage, which matters because incremental revenue should now convert better than it did over the last few quarters. That creates a path for multiple re-rating if investors start to believe the company can re-accelerate without needing a favorable one-time reimbursement event.

The biggest second-order winner is OPCH itself; the next beneficiaries are pharma partners that need a national alternate-site channel and payers looking for lower-cost site-of-care migration. The losers are hospital-owned infusion centers and any specialty distribution model that depends on captive office-administered volume, because OPCH’s hybrid billing and wider product set make it a stronger routing partner as formularies get more aggressive. The buyback also matters: at this market cap, repurchases can keep EPS compounding even if revenue only grows mid-single digits, which can mask underlying operating slippage for a few quarters.

Risk is mostly a 1-3 month catalyst gap, not a day-one issue. If CID census stalls again, or if the sequential Q3/Q4 ramp fails to show through in EBITDA, the stock can quickly de-rate because a meaningful part of the thesis is tied to execution, not just secular growth. Over 6-18 months, the falsifier is simple: if 2027 growth guidance comes in merely flat to historical instead of re-accelerating, the market will treat this as a mature services platform rather than an expanding specialty channel.

Contrarian view: the consensus may be over-optimizing the margin story. A lot of the improvement is coming from mix, process, and working-capital discipline, which are real but not infinite; once the easy fixes are done, the next leg depends on durable volume capture and successful new therapy launches. That said, the move may still be underdone if investors are underestimating how much leverage is embedded in a modest revenue re-acceleration plus ongoing buybacks.

Key Decisions for Investors

• Initiate a tactical long in OPCH on any post-earnings weakness, with a 1-3 month horizon. Risk/reward is attractive if sequential revenue and EBITDA accelerate as implied; thesis breaks if next quarter does not show visible follow-through in census and clinic utilization.
• Use a call spread in OPCH to express the 3-6 month re-acceleration thesis with limited downside. Prefer a structure that benefits from modest upside rather than a big breakout, since the market may already be pricing some self-help progress.
• Pair trade: long OPCH / short a hospital operator basket proxy such as HCA over 3-6 months to express ongoing site-of-care migration. The trade works if alternate-site infusion continues to take share from higher-cost hospital channels; cover if payer pushback or hospital-owned infusion reimbursement narrows the economics.
• Watch-list alert rather than a full position: if CID census and IG neuro growth stay positive for the next two prints, upgrade to a larger long. If either metric rolls over, reduce exposure immediately because that is the clearest falsifier of the re-acceleration narrative.
• Do not short OPCH into this print; the buyback and balance sheet reduce near-term downside, and the cleaner expression of skepticism is to wait for evidence that 2027 growth is not improving before betting against the name.